Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.3998
- Book/Share 17.2607
- PB 7.387
- Debt/Equity 0.1308
- CurrentRatio 1.5316
- ROIC 0.2092
- MktCap 158199058729.0
- FreeCF/Share 7.6589
- PFCF 16.6175
- PE 19.5431
- Debt/Assets 0.0479
- DivYield 0.0246
- ROE 0.4074
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GILD | Truist | -- | Buy | -- | $140 | Nov. 24, 2025 |
| Initiation | GILD | Scotiabank | -- | Sector Outperform | -- | $140 | Nov. 13, 2025 |
| Upgrade | GILD | Daiwa Securities | Neutral | Outperform | -- | $128 | Aug. 19, 2025 |
| Upgrade | GILD | Truist | Hold | Buy | -- | $127 | Aug. 8, 2025 |
| Upgrade | GILD | Needham | Hold | Buy | -- | $133 | July 25, 2025 |
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
| Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
News
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Markets Mixed on Powell Testimony, Q4 Earnings
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Tuesday, February 11, 2025 Market indexes were mixed today, after seeing all the majors in the red before the opening bell. The Dow closed up +123 points, +0.28%, while the S&P 500 squeaked by +2 points.
Read More
Gilead Sciences Beats Q4 EPS Forecast
Published: February 11, 2025 by: The Motley Fool
Sentiment: Positive
Gilead Sciences (GILD 0.69%), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates. Adjusted earnings per share of $1.90 came in well ahead of the estimated $1.74.
Read More
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
The Zacks Analyst Blog Uber, Comcast, Gilead Sciences and Onfolio Holdings
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Uber, Comcast, Gilead Sciences and Onfolio Holdings are included in this Analyst Blog.
Read More
3 Fabulous Dividend Stocks to Buy in February
Published: February 09, 2025 by: The Motley Fool
Sentiment: Positive
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel P. O'Day
- Employees 17600